Originally published February 26, 2017 · Updated by The Homestead Guru Editor on November 8, 2026.
People facing cancer often look beyond the first options they are offered. Stanislaw Burzynski’s antineoplaston treatment has drawn interest from patients who describe improvement and from researchers examining experimental approaches. Understanding that interest requires looking at both the favorable reports and the studies that did not find benefit.
Understand the treatment being discussed
Antineoplastons are experimental compounds developed by Burzynski. Although their history involves compounds identified in human blood and urine, the preparations discussed in clinical studies are synthesized chemicals. A description such as “naturally occurring” does not establish the safety of a concentrated treatment.
The NCI antineoplaston summary provides background on their development and published research. It was last updated in 2019 and is no longer maintained, so its discussion of ongoing trials should not be read as a current trial listing.
Scientific research: examine the reported responses
A 2014 phase 2 paper by Burzynski and colleagues reported on 17 children with recurrent diffuse intrinsic pontine glioma. It described complete response in about 6%, partial response in 23.5% and one patient alive more than 15 years after treatment.
Those findings explain some of the interest, but the study had one treatment group and no randomized comparison. It was sponsored by the Burzynski Research Institute and conducted at the Burzynski Clinic. The paper also reported serious toxicities, including high sodium levels and neurological symptoms. A reported response is not automatically a durable cure, and a selected study group does not tell every family what to expect.
Scientific research: include findings from other investigators
A 1999 phase 2 study by Buckner and colleagues treated nine adults with recurrent glioma; six were assessable for response under the protocol. No tumor regression was observed, and five patients experienced reversible neurological toxicity. The authors emphasized that the small sample prevented definitive conclusions about efficacy.
The adult study and the pediatric study involved different patient groups. They should not be treated as a direct head-to-head comparison. Together, they show why the exact diagnosis, prior treatment, study design, response assessment and independent replication matter.
Anecdotal reports: hear a patient’s reasons and experience
A 2015 account of Mary Jo Siegel’s experience on the documentary filmmaker’s website describes her reported lymphoma recovery, feeling hopeful about the clinic and taking on substantial costs. The site links documents presented as medical records.
This is a favorable advocacy account, not an independent assessment of a complete clinical history. Its claims and interpretation have not been independently verified here. Personal reports can describe what people valued and what they believe helped; they cannot supply the missing comparison group or predict another patient’s result. Promotional use of the word “non-toxic” also does not override the adverse effects reported in clinical studies.
Read dated regulatory records carefully
In its Form 10-Q filed January 13, 2026, Burzynski Research Institute stated that its antineoplaston drugs had not received FDA approval and that investigational application IND 43742 was on full clinical hold, preventing new enrollment under that application until the hold was removed. This is the company’s dated statement about that application, not a description of every service offered by the clinic or proof of today’s status.
The FDA explains that clinical trials and expanded access can involve unapproved drugs. Ask for the current documents covering the exact proposed treatment and how access is authorized. A trial number or permission to investigate is not the same as marketing approval or demonstrated benefit.
For the historical licensing proceedings, read the March 2017 Texas Medical Board decision.
Ask questions that protect your ability to choose
Bring the proposed regimen and your records to an independent cancer specialist who will discuss your priorities respectfully. Ask about evidence for your cancer type, likely benefits, serious adverse effects, monitoring, total charges and alternatives. Clarify what would trigger stopping treatment and who would manage an emergency.
Research funding and commercial interests deserve scrutiny whether a treatment is conventional or experimental. They belong alongside methods, results and independent follow-up. You can explore an option and listen to patients without being promised that it will cure you, or delaying assessment and care because of a testimonial.
